Proteome Sciences plc. (5/31/16). "Press Release: Publication of Annual Report".

	Organisation	Proteome Sciences plc
	Group	Proteome Sciences (Group)
	Organisation 2	Ikon Associates
	Product	TMT® (isobaric tandem mass tag) technology
	Product 2	PS Biomarker Services™
	Person	Pearce, Christopher (Proteome Sciences 201606– Non-executive Chairman before CEO)

The Company announces that its Annual Report and Accounts for the year ended 31 December 2015, together with a notice of the Annual General Meeting and accompanying form of proxy, are available to view on the Company’s website at www.proteomics.com, and will be posted to shareholders imminently.

[ Annual Report download at http://www.proteomics.com/docs/PS_AR_15_web-final-2.pdf ; iito ]

ENDS

For further information please contact:

Proteome Sciences plc
Christopher Pearce,
Executive Chairman
Dr. Ian Pike,
Chief Operating Officer
Tel: +44 (0)1932 865065
Geoff Ellis, Finance Director

finnCap Limited
(nominated adviser & broker)
Geoff Nash/James Thompson
Tel: +44 (0)20 7220 0500

Public Relations
IKON Associates
Email: adrian@ikonassociates.com
Adrian Shaw
Tel: +44 (0)1483 271291
Mobile +44(0)7979 900733

Notes for editors:

About Proteome Sciences plc (www.proteomics.com)

With its HQ in Cobham, UK and laboratory facilities in London and Frankfurt, Proteome Sciences is a global leader in applied proteomics offering high sensitivity, proprietary technologies and workflows in cell signalling pathways (SysQuant®, TMTcalibrator™) and in protein biomarker discovery, validation and assay development.

PS Biomarker Services® provides proteomics outsourcing services and proprietary biomarker assays from its ISO 9001:2008 facility in Frankfurt, Germany to pharmaceutical, biotechnology, diagnostics companies and academia.

Proteome Sciences’ research has discovered a large number of novel protein biomarkers in key human diseases with a focus mainly in neurological/neurodegenerative conditions and in cancer. It has patented blood biomarkers in Alzheimer’s disease, stroke, brain damage and cancers for diagnostic and treatment applications that are available for licenses.

Record changed: 2016-07-02